ReviewNano-micro letters2021
Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.
Review in Nano-micro letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 103 citations in OpenAlex.
- Cross database bibliometric and knowledge mapping analysis of nanoplatform mediated tumor associated macrophage reprogramming.Discover nano · 2026Review
- NIR-II Fluorescent Nanoplatforms with Defect-Regulated Piezoelectricity for Dual NIR-II/MRI-Guided, Hypoxia-Resilient Piezo-Chemodynamic Therapy and cGAS-STING Activation in Orthotopic Liver Tumor.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Electro-Pyroptosis Immunotherapy of Cancer via Endoplasmic Reticulum-Mitochondria Crosstalk Evoked by Ultrasound-Activated Wireless Electrostimulation.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Precision Nanotechnology: Revolutionizing Therapeutic Strategies Against Drug-Resistant Breast Cancer.Annals of biomedical engineering · 2026Review
- Thymosin α1 combined with immune checkpoint inhibitors: synergistic remodeling of the tumor immune microenvironment to enhance clinical efficacy and safety.Frontiers in immunology · 2026Review
- Photothermal therapy triggering organelle stress and metabolic reprogramming to potentiate antitumor immunity.Frontiers in immunology · 2026Review
- Exosome-Enhanced Sonodynamic Therapy in Cancer: Emerging Synergies and Modulation of the Tumor Microenvironment.Cancers · 2025Review
- Nanomaterials in gene therapy and genome editing: challenges and emerging directions.Journal of nanobiotechnology · 2025Review
- Dynamic Evolution of the Tumor Immune Microenvironment in Malignant Tumors and Emerging Therapeutic Paradigms.MedComm · 2025Review
- Extracellular vesicle microRNA cargoes: candidates for diagnosis and targeted therapy of cutaneous wound healing.Annals of medicine · 2025Review
- Biodegradable Cu-based sonozymes for tumor-specific cuproptosis-enhanced sono-immunotherapy through activating cGAS-STING pathway and sensitizing immune checkpoint blockade.Materials today. Bio · 2025Article
- Carbon dot sensitized CuJournal of nanobiotechnology · 2025Article
- AMFR-mediated ER-phagy regulation and therapeutic targeting in osteosarcoma: a multifunctional nanoplatform strategy.Journal of nanobiotechnology · 2025Article
- IR783-Stabilized Nanodrugs Enhance Anticancer Immune Response by Synergizing Oxidation Therapy and Epigenetic Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nonmetallic magnetic hyperthermia and chemo-immunotherapy of tumors.Materials today. Bio · 2025Article
- Tumor microenvironment responsive Mn-based nanoplatform activate cGAS-STING pathway combined with metabolic interference for enhanced anti-tumor therapy.Journal of nanobiotechnology · 2025Article
- Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma.World journal of surgical oncology · 2025Article
- Predictive value of dendritic cell-related genes for prognosis and immunotherapy response in lung adenocarcinoma.Cancer cell international · 2025Article
- Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment.Frontiers in immunology · 2025Review
- Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although current anticancer immunotherapies using immune checkpoint inhibitors (ICIs) have been reported with a high clinical success rate, numerous patients still bear 'cold' tumors with insufficient T cell infiltration and low immunogenicity, responding poorly to ICI therapy. Considering the advancements in precision medicine, in-depth mechanism studies on the tumor immune microenvironment (TIME) among cold tumors are required to improve the treatment for these patients. Nanomedicine has emerged as a promising drug delivery system in anticancer immunotherapy, activates immune function, modulates the TIME, and has been applied in combination with other anticancer therapeutic strategies. This review initially summarizes the mechanisms underlying immunosuppressive TIME in cold tumors and addresses the recent advancements in nanotechnology for cold TIME reversal-based therapies, as well as a brief talk about the feasibility of clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.